Brief: Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
23/10/2025 13:06
Oct 23 (Reuters) - Grace Therapeutics, Inc GRCE.O: GRACE THERAPEUTICS SECURES APPROXIMATELY $4.0 MILLION THROUGH COMMON WARRANT EXERCISES FOLLOWING ACCEPTANCE OF NEW DRUG APPLICATION FOR GTX-104 FOR FORMAL FDA REVIEW GRACE THERAPEUTICS, INC - FDA SETS PDUFA TARGET DATE OF APRIL 23, 2026 FOR GTX-104 Source text: ID:nGNXbl0CMW Further company coverage: GRCE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grace Therapeutics
See all newsBrief: Grace Therapeutics - Selling Stockholders May Resell Up To 4,761,904 Shares Of Common Stock - SEC Filing
Grace Therapeutics Q1 net loss widens on impairment charges
Grace Therapeutics falls after FDA declines to approve stroke drug
NASDAQ RESUMED AT 01:57 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:52 PM